Researchers are excited about this new drug, a innovative dual agonist showing remarkable outcomes in clinical trials for size loss . It acts by targeting both pathways : GLP-1 and GIP, which , when activated , assist regulate hunger and boost metabolism . Initial findings indicate considerable body reduction and possible advantages for patients… Read More